Oritavancin Diphosphate is primarily used as an antibiotic to treat serious bacterial infections, particularly those caused by Gram-positive bacteria. It is effective against skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The drug is administered intravenously and is valued for its long half-life, allowing for a single-dose treatment regimen. This makes it a convenient option for patients who may have difficulty adhering to multiple-dose therapies. Oritavancin works by inhibiting cell wall synthesis and disrupting bacterial membrane integrity, leading to bacterial cell death. Its application is especially important in hospital settings where resistant bacterial strains are a concern.